2020
Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters
Rank M, Sharaf R, Furuta G, Aceves S, Greenhawt M, Spergel J, Falck-Ytter Y, Dellon E, Institute A, Chachu K, Day L, Lebwohl B, Muniraj T, Patel A, Peery A, Shah R, Singh H, Singh S, Spechler S, Sultan S, Su G, Thrift A, Weiss J, Weizman A, collaborators J, Bernstein J, Dinakar C, Golden D, Khan D, Lieberman J, Oppenheimer J, Shaker M, Stukus D, Wallace D, Wang J. Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters. Annals Of Allergy Asthma & Immunology 2020, 124: 424-440.e17. PMID: 32336463, PMCID: PMC8171057, DOI: 10.1016/j.anai.2020.03.021.Peer-Reviewed Original ResearchConceptsShort-term treatment periodEsophageal eosinophil countsHigh-power fieldLow certaintyTopical glucocorticosteroidsModerate certaintyEosinophilic esophagitisEosinophil countTreatment periodPractice parametersAmerican Gastroenterological Association InstituteAnti-IgE therapyAnti-TNF therapyChronic inflammatory conditionsProton pump inhibitorsJoint Task ForceDiet eliminationDietary eliminationElimination dietEoE managementEsophageal eosinophiliaMaintenance therapyRecommendations AssessmentElemental dietEsophageal dilationTechnical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters
Rank M, Sharaf R, Furuta G, Aceves S, Greenhawt M, Spergel J, Falck-Ytter Y, Dellon E, Institute A, Chachu K, Day L, Lebwohl B, Muniraj T, Patel A, Peery A, Shah R, Singh H, Singh S, Spechler S, Sultan S, Su G, Thrift A, Weiss J, Weizman A, collaborators J, Bernstein J, Dinakar C, Golden D, Khan D, Lieberman J, Oppenheimer J, Shaker M, Stukus D, Wallace D, Wang J. Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. Gastroenterology 2020, 158: 1789-1810.e15. PMID: 32359563, PMCID: PMC9473155, DOI: 10.1053/j.gastro.2020.02.039.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAdultAdvisory CommitteesAge FactorsAllergy and ImmunologyChildDilatationEosinophilic EsophagitisEosinophilsEsophagoscopyEvidence-Based MedicineFood HypersensitivityFood, FormulatedGastroenterologyGlucocorticoidsHumansProton Pump InhibitorsSocieties, MedicalTreatment OutcomeUnited StatesConceptsShort-term treatment periodEsophageal eosinophil countsHigh-power fieldLow certaintyTopical glucocorticosteroidsModerate certaintyEosinophilic esophagitisEosinophil countTreatment periodPractice parametersAmerican Gastroenterological Association InstituteAnti-IgE therapyAnti-TNF therapyChronic inflammatory conditionsProton pump inhibitorsJoint Task ForceDiet eliminationDietary eliminationElimination dietEoE managementEsophageal eosinophiliaMaintenance therapyRecommendations AssessmentElemental dietEsophageal dilation
2016
Pharmacologic Therapies in Gastrointestinal Diseases
Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Medical Clinics Of North America 2016, 100: 827-850. PMID: 27235617, DOI: 10.1016/j.mcna.2016.03.009.Peer-Reviewed Original ResearchMeSH KeywordsAntacidsAnti-Bacterial AgentsAntidepressive AgentsAntidiarrhealsAntiviral AgentsCoinfectionDietary FiberDrug Resistance, ViralGastroesophageal RefluxGastrointestinal AgentsGastrointestinal DiseasesGenotypeHelicobacter InfectionsHepatitis CHistamine H2 AntagonistsHIV InfectionsHumansIrritable Bowel SyndromeLaxativesPeptic UlcerProbioticsProton Pump InhibitorsConceptsGastroesophageal reflux diseaseIrritable bowel syndromeProton pump inhibitorsHepatitis C virusBowel syndromeFirst-line treatmentMainstay of therapyPeptic ulcer diseaseLong-term useHCV treatmentReflux diseaseMost patientsPharmacologic therapyDuodenal ulcerUlcer diseasePump inhibitorsC virusGastrointestinal diseasesTreatment candidatesPermanent cureSevere symptomsSide effectsDiseaseHigher likelihoodPharmacotherapy